Login / Signup

The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.

Caroline S BennetteCarlos J GallegoWylie BurkeGail P JarvikDavid L Veenstra
Published in: Genetics in medicine : official journal of the American College of Medical Genetics (2014)
Returning incidental findings is likely cost-effective for certain patient populations. Screening of generally healthy individuals is likely not cost-effective based on current data, unless next-generation sequencing costs less than $500.
Keyphrases
  • copy number
  • case report
  • electronic health record
  • single cell
  • big data
  • circulating tumor
  • dna methylation
  • genome wide
  • gene expression
  • machine learning